Copper-dependent cell death, a new key to Alzheimer's treatment
Background and Challenges
Alzheimer's disease (AD) accounts for over 60% of dementia patients worldwide, yet a fundamental cure remains elusive. Previous research focused primarily on beta-amyloid (Aβ) plaques and tau hyperphosphorylation, but consistently reports abnormally elevated copper (Cu) levels in the brains of patients. Recent evidence suggests that copper overload disrupts tricarboxylic acid (TCA) cycle enzymes within mitochondria and causes lipoylated proteins to aggregate. This mechanism presents a direct link between copper and mitochondrial metabolism, distinct from conventional cell death pathways. Therefore, new therapeutic strategies that regulate copper imbalance are urgently needed.
Research Methods and Key Findings
The research team quantified changes in the expression of copper transporters CTR1 (SLC31A1) and ATP7A in AD model mice and human brain tissue. They demonstrated that copper overload promotes lipoylation of TCA cycle enzymes, such as DLST (dihydrolipoamide succinyltransferase), within mitochondria, leading to protein aggregation and destabilization of Fe-S clusters. The resulting oxidative stress accelerates neuronal loss and synergizes with Aβ and tau pathologies, exacerbating disease progression. Furthermore, administration of copper chelators, such as trientine, and CTR1 inhibitors, such as PiSTON, significantly reduced the accumulation of lipoylated proteins and restored memory function in behavioral tests. These findings present a new paradigm, suggesting that copper-dependent cell death, or cuproptosis, plays a critical role in AD pathogenesis.
Therapeutic Strategies and Current Status
The research team is currently exploring multi-pronged approaches to block cuproptosis. Copper chelators, such as trientine and diamine, restore copper levels in the brain to normal ranges, inhibiting mitochondrial damage, while the antioxidant coenzyme Q10 neutralizes excessive ROS, enhancing neuroprotective effects. Strategies are also underway to promote copper excretion by correcting the ATP7A gene using CRISPR/Cas9 gene editing technology and to prevent protein aggregation by inhibiting the lipoylation enzyme LIPT1. In the field of immunotherapy, antibody-based therapies targeting copper-mediated inflammation have shown promising results in preclinical studies, and some pharmaceutical companies have already entered phase 2 clinical trials. However, copper is an essential mineral for neurotransmission and enzyme activity, so excessive inhibition may cause side effects, making precise dose control a key challenge.
Future Significance and Prospects
The establishment of the cuproptosis concept has opened new avenues for AD drug development. In the future, personalized medicine combining patient-specific copper metabolism profiles with tailored chelator administration and gene editing therapy is likely to become a reality. Furthermore, the development of biomarkers that can simultaneously monitor copper and mitochondrial metabolism is underway, which will revolutionize early diagnosis and therapeutic response assessment. Companies are currently building pipelines of cuproptosis-targeted drugs, and investment is expected to expand, targeting a global AD drug market of 1 trillion won by 2028. Ultimately, there is growing hope that restoring copper balance will be the key to fundamentally inhibiting AD progression.
Alzheimer's disease (AD), a leading cause of dementia, remains incurable, necessitating novel insights into its pathogenesis and therapeutic strategies. Recent studies highlight cuproptosis-a copper (Cu)-dependent mitochondrial cell death pathway-as a critical player in AD progression. Cuproptosis is triggered by Cu overload, which disrupts mitochondrial tricarboxylic acid cycle enzymes, resulting in toxic aggregation of lipoylated proteins and iron-sulfur cluster destabilization. This process exacerbates mitochondrial dysfunction, oxidative stress, and neuronal loss, synergizing with hallmark AD pathologies like Aβ deposition and Tau hyperphosphorylation. Unlike ferroptosis or apoptosis, cuproptosis uniquely involves mitochondrial protein lipoylation and Cu homeostasis imbalance. Therapeutic strategies targeting cuproptosis include Cu chelators, inhibitors of Cu transporters, antioxidants, and gene editing approaches to restore Cu homeostasis or mitigate protein aggregation. Immunotherapy and neuroprotective agents further show promise in alleviating cuproptosis-driven neuroinflammation. Despite preclinical advancements, challenges remain in balancing Cu's essential roles with therapeutic interventions. This review underscores cuproptosis as a pivotal mechanism in AD and outlines emerging therapeutic avenues, emphasizing the necessity for precision in targeting Cu dysregulation to halt neurodegeneration.
Alzheimer's disease affects over 50 million people worldwide and is a leading cause of dementia. Current treatments only alleviate symptoms, and a cure is urgently needed. Previous treatments focused on Aβ and tau, but most failed in phase 3 clinical trials due to limited efficacy or side effects. This research presents cuproptosis, a copper-dependent cell death pathway, as a new mechanism in AD, offering an innovative approach beyond existing limitations. As a result, trientine-based therapies are currently in phase 2 clinical trials and are expected to be a new growth driver in the $15 billion Alzheimer's drug market. In the future, gene editing and personalized chelator therapies that precisely regulate copper metabolism are expected to enter the commercialization stage, ushering in an era of personalized medicine for patients.